At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 97 enrolled
Drug / intervention
AZD2281 +2 moredrug
Likely dose
AZD2281 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-based Chemotherapy
In Brief
A Phase 2 clinical trial evaluating AZD2281 and Liposomal Doxorubicin for Ovarian Neoplasms. Completed, enrolled 97 participants across 24 sites in 9 countries.
Detailed Summary
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasms
CountriesAustralia, Belgium, Germany, Israel, Poland, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartJul 2008
Primary CompletionSep 2009
Study CompletionSep 2018
TodayJul 2026
First PostedMar 5, 2008
Enrollment StartJul 30, 2008
Primary CompletionSep 15, 2009
Study CompletionSep 19, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.3 years ago
Interventions
AZD2281drug
400mg Oral twice daily
Liposomal Doxorubicindrug
50mg/m2 Monthly Intravenous
AZD2281drug
200mg oral twice daily